Welcome to our dedicated page for Lexeo Therapeutics SEC filings (Ticker: LXEO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Lexeo Therapeutics, Inc. filings document a clinical-stage cardiovascular genetic medicine company and its formal disclosures on operations, pipeline progress, governance, and capital resources. Recent 8-K reports furnish financial results, business highlights, corporate presentations, and clinical updates for AAV gene therapy programs including LX2006 and LX2020.
The company’s SEC record also covers Regulation FD materials, CMC and regulatory-update disclosures, leadership transitions, director appointments, compensatory arrangements, and proxy matters for annual stockholder meetings. Its definitive proxy statement addresses board service, committee structure, voting proposals, executive compensation, and other governance information relevant to Lexeo’s public-company oversight.
Lexeo Therapeutics, Inc. Chief Executive Officer Richard Nolan Townsend reported an open-market sale of 10,173 shares of common stock at a weighted average price of $6.382 per share. According to the footnotes, this sale was made to cover tax obligations on the release of restricted stock units. Following the transaction, he directly holds 392,483 shares, which include 261,349 restricted stock units.
Lexeo Therapeutics, Inc. Chief Operating Officer Jose Manuel Otero corrected a prior insider trade report and detailed a small tax-related sale of shares. An earlier Form 4 had mistakenly stated that a sale to cover tax obligations occurred on August 18, 2025. This amendment clarifies that the open-market sale of 721 shares of common stock actually took place on November 18, 2025 at a weighted average price of $9.27 per share, executed in multiple trades between $9.09 and $9.37. The sale was made solely to cover tax obligations from the release of restricted stock units. After this transaction, Otero directly owns 63,476 shares of Lexeo Therapeutics common stock, including 47,733 RSUs, so his overall stake in the company remains largely unchanged.
LXEO Form 144 filing reports planned resale of 11,374 common shares tied to restricted stock vesting. The filing lists a restricted stock vesting transaction dated 02/17/2026 showing 11,374 shares as "Securities To Be Sold" and notes prior sales of 1,127 shares on 11/18/2025.
LXEO notice of proposed sale of 3,016 common shares. The filing lists 3,016 shares as "Securities To Be Sold" with an event labeled Restricted Stock Vesting dated 02/17/2026. It also shows 721 common shares sold on 11/18/2025 as a prior three‑month disposition.
LXEO submitted a Form 144 reporting the proposed sale of 3,861 common shares tied to restricted stock vesting on 02/17/2026. The filing lists Fidelity Brokerage Services LLC as a broker/firm with a trade date of 02/18/2026 and indicates NASDAQ as the market.
LXEO reported a proposed sale of 3,736 common shares via Fidelity Brokerage Services following restricted stock vesting on 02/17/2026. The filing lists a dollar figure of $23,896.58 associated with the securities and notes a prior sale of 549 shares on 11/18/2025 by Jenny R. Robertson.
LXEO affiliate files to sell 02/17/2026 a total of 4,867 common shares under a Form 144 notice. The filing states these shares arise from restricted stock vesting and were designated as compensation.
The filing also discloses 615 shares sold during the prior three months (date 11/18/2025). Timing and specific broker execution details are provided in the notice.
Lexeo Therapeutics’ Chief Medical Officer Narinder Pal Bhalla received new equity awards in the form of stock options and restricted stock units. On February 13, 2026, he was granted 297,000 stock options with a $6.31 exercise price and 49,500 RSUs, both at no cash cost to him.
The option grant vests with 25% of the underlying shares becoming exercisable on January 20, 2027, and the remaining 75% vesting in equal monthly installments over the following three years, contingent on continuous service. The RSUs vest 25% on February 15, 2027, with the rest vesting in equal quarterly installments thereafter, also subject to continued service.
Citadel-affiliated investment entities filed an amended Schedule 13G reporting beneficial ownership in Lexeo Therapeutics, Inc. common stock. The filing states that Kenneth Griffin may be deemed to beneficially own 5,498,219 Shares, representing 7.4% of Lexeo’s outstanding common stock.
Citadel Advisors LLC, Citadel Advisors Holdings LP and Citadel GP LLC may each be deemed to beneficially own 5,405,269 Shares, or 7.2% of the class, while certain Citadel Securities entities report smaller positions of 6,600 and 92,950 Shares. The percentages are based on 74,704,629 Shares outstanding, including 1,717,302 Shares issuable upon warrant conversion. The reporting persons certify the securities are not held to change or influence control of Lexeo.
Lexeo Therapeutics, Inc. (LXEO) received an amended Schedule 13G filing showing that Paradigm BioCapital entities and managing member Senai Asefaw, M.D. collectively report beneficial ownership of 4,763,198 shares of common stock, or 6.5% of the company, as of December 31, 2025.
Within this total, Paradigm BioCapital International Fund Ltd. reports 4,207,159 shares, representing 5.8% of Lexeo’s common stock. The filing states that these securities were not acquired and are not held for the purpose of changing or influencing control of Lexeo, indicating a passive investment intent under the applicable rules.